637 related articles for article (PubMed ID: 25928457)
1. A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis.
Wu PF; Lin CH; Kuo CH; Chen WW; Yeh DC; Liao HW; Huang SM; Cheng AL; Lu YS
BMC Cancer; 2015 Apr; 15():299. PubMed ID: 25928457
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis.
Chen IC; Lin CH; Jan IS; Cheng AL; Lu YS
J Formos Med Assoc; 2016 Apr; 115(4):243-8. PubMed ID: 25890495
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy.
Lu YS; Chen TW; Lin CH; Yeh DC; Tseng LM; Wu PF; Rau KM; Chen BB; Chao TC; Huang SM; Huang CS; Shih TT; Cheng AL;
Clin Cancer Res; 2015 Apr; 21(8):1851-8. PubMed ID: 25700303
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
6. A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.
Chen BB; Lu YS; Lin CH; Chen WW; Wu PF; Hsu CY; Yu CW; Wei SY; Cheng AL; Shih TT
BMC Cancer; 2016 Jul; 16():466. PubMed ID: 27412562
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatment of breast cancer with leptomeningeal metastases using bevacizumab, etoposide and cisplatin (BEEP regimen) significantly improves overall survival.
Chen TW; Jan IS; Chang DY; Lin CH; Chen IC; Chen HM; Cheng AL; Lu YS
J Neurooncol; 2020 May; 148(1):165-172. PubMed ID: 32346837
[TBL] [Abstract][Full Text] [Related]
8. Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial.
Tiseo M; Boni L; Ambrosio F; Camerini A; Vitale MG; Baldini E; Cinieri S; Zanelli F; Defraia E; Passalacqua R; Crino L; Dazzi C; Tibaldi C; Turolla GM; D'Alessandro V; Zilembo N; Riccardi F; Ardizzoni A;
Clin Lung Cancer; 2015 Jan; 16(1):67-70. PubMed ID: 25450879
[TBL] [Abstract][Full Text] [Related]
9. Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis.
Park WY; Kim HJ; Kim K; Bae SB; Lee N; Lee KT; Won JH; Park HS; Lee SC
Cancer Res Treat; 2016 Apr; 48(2):843-7. PubMed ID: 25761487
[TBL] [Abstract][Full Text] [Related]
10. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T;
Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
[TBL] [Abstract][Full Text] [Related]
12. Molecular detection of human mammaglobin in cerebrospinal fluid from breast cancer patient with leptomeningeal carcinomatosis.
Dono M; Ferro P; Benedetti L; Capellini C; Moroni M; Dessanti P; Bacigalupo B; Tartaglione A; Battolla E; Fedeli F; Roncella S
J Neurooncol; 2009 Feb; 91(3):295-8. PubMed ID: 18841443
[TBL] [Abstract][Full Text] [Related]
13. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab plus docetaxel and cisplatin for metastatic breast cancer: a pilot phase II study.
Tai CJ; Chen CS; Hung CS; Kuo LJ; Wei PL; Chiou JF; Hsu CH; Chiou HY; Wu CH
Anticancer Res; 2012 Dec; 32(12):5501-6. PubMed ID: 23225458
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of Systemic High-dose Methotrexate and Intrathecal Liposomal Cytarabine for Treatment of Leptomeningeal Carcinomatosis From Breast Cancer.
Mrugala MM; Kim B; Sharma A; Johnson N; Graham C; Kurland BF; Gralow J
Clin Breast Cancer; 2019 Oct; 19(5):311-316. PubMed ID: 31175053
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
17. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.
Franciosi V; Cocconi G; Michiara M; Di Costanzo F; Fosser V; Tonato M; Carlini P; Boni C; Di Sarra S
Cancer; 1999 Apr; 85(7):1599-605. PubMed ID: 10193952
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
Spigel DR; Townley PM; Waterhouse DM; Fang L; Adiguzel I; Huang JE; Karlin DA; Faoro L; Scappaticci FA; Socinski MA
J Clin Oncol; 2011 Jun; 29(16):2215-22. PubMed ID: 21502556
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
Cameron D; Brown J; Dent R; Jackisch C; Mackey J; Pivot X; Steger GG; Suter TM; Toi M; Parmar M; Laeufle R; Im YH; Romieu G; Harvey V; Lipatov O; Pienkowski T; Cottu P; Chan A; Im SA; Hall PS; Bubuteishvili-Pacaud L; Henschel V; Deurloo RJ; Pallaud C; Bell R
Lancet Oncol; 2013 Sep; 14(10):933-42. PubMed ID: 23932548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
